跳至主要内容
临床试验/JPRN-UMIN000000564
JPRN-UMIN000000564已完成2 期

Phase II trial of docetaxel and carboplatin in patients with stage IVb or recurrent nonsquamous cell carcinoma of uterine cervix - Phase II trial of docetaxel and carboplatin in patients with stage IVb or recurrent nonsquamous cell carcinoma of uterine cervix

Sankai Gynecology Study Group0 个研究点目标入组 50 人开始时间: 2007年1月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
50

研究概览

简要总结

The response rate was 47.9% with 5 patients achieving complete response, 18 partial response, 14 stable disease, and 6 progressive disease. The disease control rate was 77.1%. With a median follow-up duration of 368 days, the median progression-free survival and overall survival were 6.1 months (95% CI 5.5-8.6) and 15.8 months (95% CI 18.2-28.3), respectively.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1.Fever with over 38.0C 2.Infection or WBC>12,000/mm3 3.Severe complications 4.Neuropathy >Grade 2 5.Edema > Grade 2 6.Double cancer 7.Massive pleural effusion and ascites 8.Hypersensitivity reactions to docetaxel or carboplatin 9.Patients judged as exclusive case by the investigator

研究者

发起方
Sankai Gynecology Study Group

相似试验